Filing Flows › Alkermes (ALKS) › Q3 2025
Alkermes (ALKS) Q3 2025 earnings results (third quarter 2025)
10-Q filed Oct 28, 2025
Alkermes (ALKS) reported revenue of $394M for the third quarter 2025 (Q3 2025), +4% from a year earlier and +0.9% from the quarter before. Operating margin was 22.6%, net earnings $82.8M (21.0% of revenue).
Alkermes, Q3 2025: revenue $394M (+4% year over year), operating margin 22.6%, net earnings $82.8M, operating cash flow $102M. The chart follows the revenue to costs, profit and cash.
| Q3 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $394M | +0.9% | +4% |
| Operating profit | $89.1M | -4% | -15% |
| Net earnings | $82.8M | -5% | -10% |
| Operating cash flow | $102M | -32% | +25% |
| Free cash flow | $84.4M | -39% | +15% |
What changed
Revenue was $394.2M in Q3 2025, up 4% year over year and up 1% from the previous quarter. Vivitrol was the largest line at 31% of revenue. LYBALVI added $23.6M year over year (up 32%), 147% of the total change. Manufacturing Revenue declined 45%.
Operating profit was $89.1M, a 22.6% margin (down 5.1 points year over year). Operating profit fell $15.7M even though revenue rose $16.0M versus a year earlier, so costs grew faster than sales. Total costs grew 12% against revenue growth of 4%. The fastest-growing cost line was Research & development (+36%). Net earnings were $82.8M, down 10% year over year. The effective tax rate was 17.9%.
Operating cash flow was $101.7M (up 25% year over year), 123% of net earnings. Non-cash charges added back $8.1M of depreciation and amortization and $24.7M of share-based compensation. Working capital and other items used $13.8M. Capital expenditures of $17.3M left free cash flow of $84.4M.
Questions
What was Alkermes' revenue in the third quarter 2025?
Alkermes (ALKS) reported revenue of $394M for the third quarter 2025 (Q3 2025), +4% from a year earlier and +0.9% from the quarter before.
Was Alkermes profitable in the third quarter 2025?
Operating profit was $89.1M (22.6% of revenue) and net earnings $82.8M.
Source: Alkermes 10-Q on SEC EDGAR.